BACKGROUND: Symptom improvement in irritable bowel syndrome (IBS) treatment trials varies widely, with only 50-70% of patients qualifying as responders. Factors predicting treatment responsiveness are not known, although we have demonstrated that symptom improvement with the 5-HT3R antagonist alosetron is correlated with reduced amygdala activity. AIM: To determine whether neural activity during rectal discomfort or psychological distress predicts symptom improvement following treatment with alosetron. METHODS:Basal psychological distress and neural activity (15O PET) during uncomfortable rectal stimulation were measured in 17 nonconstipated IBS patients who then received 3 weeks of alosetron treatment. RESULTS: Greater symptom improvement was predicted by less activity in bilateral orbitofrontal cortex (OFC) and medial temporal gyrus during pre-treatment scans. Lower levels of interpersonal sensitivity predicted greater symptom improvement and were positively related to activity in left OFC. Connectivity analysis revealed a positive relationship between activity in the left OFC and right amygdala. CONCLUSIONS: Irritable bowel disease symptom improvement with 5-HT3R antagonist alosetron is related to pre-treatment reactivity of the left OFC, which may be partially captured by subjective measures of interpersonal sensitivity. The left OFC may fail to modulate amygdala response to visceral stimulation, thereby diminishing effectiveness of treatment. Psychological factors and their neurobiological correlates are plausible predictors of IBS treatment outcome.
RCT Entities:
BACKGROUND: Symptom improvement in irritable bowel syndrome (IBS) treatment trials varies widely, with only 50-70% of patients qualifying as responders. Factors predicting treatment responsiveness are not known, although we have demonstrated that symptom improvement with the 5-HT3R antagonist alosetron is correlated with reduced amygdala activity. AIM: To determine whether neural activity during rectal discomfort or psychological distress predicts symptom improvement following treatment with alosetron. METHODS: Basal psychological distress and neural activity (15O PET) during uncomfortable rectal stimulation were measured in 17 nonconstipated IBSpatients who then received 3 weeks of alosetron treatment. RESULTS: Greater symptom improvement was predicted by less activity in bilateral orbitofrontal cortex (OFC) and medial temporal gyrus during pre-treatment scans. Lower levels of interpersonal sensitivity predicted greater symptom improvement and were positively related to activity in left OFC. Connectivity analysis revealed a positive relationship between activity in the left OFC and right amygdala. CONCLUSIONS:Irritable bowel disease symptom improvement with 5-HT3R antagonist alosetron is related to pre-treatment reactivity of the left OFC, which may be partially captured by subjective measures of interpersonal sensitivity. The left OFC may fail to modulate amygdala response to visceral stimulation, thereby diminishing effectiveness of treatment. Psychological factors and their neurobiological correlates are plausible predictors of IBS treatment outcome.
Authors: Jason L Stein; Lisa M Wiedholz; Danielle S Bassett; Daniel R Weinberger; Caroline F Zink; Venkata S Mattay; Andreas Meyer-Lindenberg Journal: Neuroimage Date: 2007-03-28 Impact factor: 6.556
Authors: B D Naliboff; S W Derbyshire; J Munakata; S Berman; M Mandelkern; L Chang; E A Mayer Journal: Psychosom Med Date: 2001 May-Jun Impact factor: 4.312
Authors: E A Mayer; S Berman; S W G Derbyshire; B Suyenobu; L Chang; L Fitzgerald; M Mandelkern; L Hamm; B Vogt; B D Naliboff Journal: Aliment Pharmacol Ther Date: 2002-07 Impact factor: 8.171
Authors: Steven M Berman; Lin Chang; Brandall Suyenobu; Stuart W Derbyshire; Jean Stains; Leah Fitzgerald; Mark Mandelkern; Lynn Hamm; Brent Vogt; Bruce D Naliboff; Emeran A Mayer Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: Lisa A Kilpatrick; Jennifer S Labus; Kristen Coveleskie; Christian Hammer; Gudrun Rappold; Kirsten Tillisch; Joshua A Bueller; Brandall Suyenobu; Johana M Jarcho; Jim A McRoberts; Beate Niesler; Emeran A Mayer Journal: Gastroenterology Date: 2011-03-21 Impact factor: 22.682
Authors: Brennan M R Spiegel; Dinesh Khanna; Roger Bolus; Nikhil Agarwal; Puja Khanna; Lin Chang Journal: Am J Gastroenterol Date: 2011-03 Impact factor: 10.864
Authors: E Kokkotou; L A Conboy; D C Ziogas; M T Quilty; J M Kelley; R B Davis; A J Lembo; T J Kaptchuk Journal: Neurogastroenterol Motil Date: 2009-12-22 Impact factor: 3.598
Authors: Bruce D Naliboff; Sharon E Kim; Roger Bolus; Charles N Bernstein; Emeran A Mayer; Lin Chang Journal: Am J Gastroenterol Date: 2011-11-15 Impact factor: 10.864
Authors: A Shiotani; H Kusunoki; M Ishii; H Imamura; N Manabe; T Kamada; J Hata; J L Merchant; K Haruma Journal: Neurogastroenterol Motil Date: 2014-11-27 Impact factor: 3.598